Zydus Lifesciences Limited (NSE: ZYDUSLIFE)
India
· Delayed Price · Currency is INR | Market Cap | 1.11T |
| Revenue (ttm) | 206.15B |
| Net Income (ttm) | 41.93B |
| Shares Out | 1.01B |
| EPS (ttm) | 41.49 |
| PE Ratio | 26.67 |
| Forward PE | 24.02 |
| Dividend | 3.00 (0.27%) |
| Ex-Dividend Date | Jul 26, 2024 |
| Volume | 1,307,196 |
| Open | 1,118.85 |
| Previous Close | 1,115.15 |
| Day's Range | 1,097.20 - 1,120.00 |
| 52-Week Range | 567.75 - 1,324.30 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2024 |
About Zydus Lifesciences
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management... [Read more]
Financial Performance
In 2023, ZYDUSLIFE's revenue was 195.47 billion, an increase of 13.40% compared to the previous year's 172.37 billion. Earnings were 38.60 billion, an increase of 96.88%.
Financial StatementsNews
Zydus Lifesciences gets warning letter from USFDA for injectables manufacturing facility at Jarod
Zydus Lifesciences informed exchanges on Tuesday that it has received a warning notice from the USFDA regarding its injectables manufacturing facility at Jarod near Vadodara. The USFDA’s Warning Lette...
Zydus’ injectables mfg plant gets USFDA warning letter
Zydus Lifesciences' injectables manufacturing plant in Jarod near Vadodara receives a warning letter from USFDA for violations of manufacturing regulations. No data integrity issues reported.
Zydus Lifesciences gets warning letter from USFDA relating to its injectables manufacturing facility in Jarod
Zydus Lifesciences recently informed the exchanges that the USFDA issued a warning letter regarding its injectables manufacturing facility in Jarod, near Vadodara. The warning letter details violation...
Zydus Lifesciences receives US FDA approval for Scopolamine Patch, eyeing $69.6 Million US Market
Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) to market S...
Zydus Lifesciences stock surges over 2% following Sterling Biotech stake acquisition
Zydus Lifesciences Limited (NSE: ZYDUSLIFE) shares are trading significantly higher today following the company’s announcement of its successful acquisition of a 50% equity stake in Sterling Biotech L...
Zydus Lifesciences completes acquisition of 50% stake in Sterling Biotech
Zydus Lifesciences Limited, a prominent pharmaceutical company, has announced the successful completion of its acquisition of a 50% equity stake in Sterling Biotech Limited. The transaction was finali...
Stocks to Watch: Medi Assist, HCLTech, Zydus Lifesciences, Ultra Tech, HUL shares in focus Today, 27 Aug, 2024
The US market Dow touched lifetime highs in yesterday’s trading session, and we are expecting the Nifty to hit an all-time high today. With the global market trading mixed, several companies are in th...
Stock Market Today: Top gainers and losers in market today, August 26, 2024; KEC International, NIIT, ONGC, Paytm, Zydus Lifesciences and more
On August 26, the stock market closed on a strong note as benchmark indices Nifty and Sensex gained momentum, primarily driven by positive performances in metal and IT stocks. The market was also buoy...
Citi maintains its Sell call on Zydus, expressed concerns over Sterling Biotech deal
Zydus Lifesciences shares tumbled to a nearly two-month low on Monday, following the company's announcement of a 50% stake acquisition in Sterling Biotech Ltd. for Rs 550 crore.
Zydus Lifesciences shares dip 4% after acquisition of stake in Sterling Biotech
Shares of Zydus Lifesciences fell by 4.03% to ₹1,130.50 as of 10:30 AM on Monday, following news of the company’s strategic move in the biopharmaceutical sector. Zydus Lifesciences, through its wholly...
Zydus to acquire 50% stake in Sterling Biotech
Zydus Lifesciences Limited acquires 50% stake in Sterling Biotech through a joint venture with Perfect Day Inc, entering the fermentation-based protein sector.
Zydus to buy 50% stake in Sterling Biotech
Zydus Lifesciences and Perfect Day Inc to acquire 50% stake in Sterling Biotech, leading producer of pharmaceutical Gelatine and Di-Calcium Phosphate. Joint venture to focus on fermentation-based prot...
Zydus Lifesciences Q1 profit up 31%
Zydus Lifesciences Ltd recorded a 31% increase in net profit in the first quarter of FY25. Revenue from operations also saw a significant rise. Read more about the financial performance of Zydus Lifes...